GHRP-2 Research for GH Deficiency Diagnosis
An evidence-based overview of research examining GHRP-2 in the context of gh deficiency diagnosis. This page synthesizes findings from peer-reviewed literature.
Research Summary
GHRP-2 (as Pralmorelin) is approved in Japan for diagnosing growth hormone deficiency. The compound produces consistent, potent GH release that allows assessment of pituitary reserve. Phase 2/3 trials demonstrated comparable sensitivity and specificity to the insulin tolerance test with a superior safety profile.
Referenced Studies
Click any PMID to view the full study on PubMed.
Other Peptides Studied for GH Deficiency Diagnosis
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. GHRP-2 may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.